Hologic (HOLX) announced that its Affirm Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate biopsy procedures, is now CE-marked. The technology received clearance from the FDA in October 2020. Designed from the ground up to integrate with the Selenia Dimensions and 3Dimensions systems, Hologic’s Affirm Contrast Biopsy Software enables clinicians to target and acquire tissue samples in lesions identified through contrast-enhanced mammography.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic announces FDA clearance of Aptima SARS-CoV-2 assay
- Hologic’s Earnings Call: Mixed Outlook Amidst Growth and Challenges
- Hologic price target lowered to $85 from $88 at RBC Capital
- Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls
- Hologic price target lowered to $90 from $95 at Raymond James
Questions or Comments about the article? Write to editor@tipranks.com